Arrowhead Pharmaceuticals' Exciting December 2024 Conference Lineup

Arrowhead Pharmaceuticals to Engage at December Conferences

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has exciting participations lined up for December 2024. With several key conferences approaching, Arrowhead aims to showcase its innovative advancements in RNA-based therapeutics and engage with healthcare professionals and stakeholders in the industry.

Key Conferences and Participation

Among the notable events is the Piper Sandler 36th Annual Healthcare Conference scheduled for December 3-5, 2024. This platform will feature a fireside chat presentation on December 3 at 1:30 p.m. EST, making it an excellent opportunity for discussions on future healthcare innovations.

Evercore ISI HealthCONx Conference

Simultaneously, Arrowhead will present at the 7th Annual Evercore ISI HealthCONx Conference from December 3-5, 2024. The firm is set to host another fireside chat, this time on December 4 at 2:10 p.m. EST.

Scientific Contributions at Noteworthy Meetings

A crucial aspect of Arrowhead’s agenda is the participation in the APA/JPS/CAP 2024 Joint Meeting from December 9-12. Here, they will present on the PALISADE Phase 3 study assessing the efficacy and safety of Plozasiran for adults with genetically or clinically-defined Familial Chylomicronemia Syndrome. This significant study discusses risks associated with acute pancreatitis and takes place on December 9 at 12:00 p.m. HST.

Further Connections in RNA Therapeutics

In addition to these events, Arrowhead Pharmaceuticals will be part of the RNA at the Bench and Bedside IV conference during the same dates. Their presentation titled "Developing siRNA for Neurodegenerative Disorders" is scheduled for December 9 at 2:10 p.m. PST, featuring insights into pre-clinical RNA therapeutics.

Global CVCT Forum

The 21st Global CVCT Forum running from December 9-11 will also host Arrowhead's discussions on a randomized, placebo-controlled Phase 3 study of Plozasiran in patients with Familial Chylomicronemia Syndrome. Arrowhead expects to engage closely with peers and other stakeholders on December 10 at 7:30 p.m. EST.

Complement-Based Drug Development Summit

The 8th Complement-Based Drug Development Summit is another key event slated for December 10-11. Arrowhead will delve deeper into therapies targeting complement C3 and Factor B, providing a session on December 11 at 10:00 a.m. EST, assessing advances in complement therapies.

Expanding Presence at the WCIRDC

Furthermore, Arrowhead will join the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) from December 12-14. They will revisit the PALISADE study on December 13 from 7:30-9:00 a.m. PST, showcasing their commitment to innovative research in cardiovascular diseases.

Accessing Presentation Materials

All presentation materials from these upcoming events will be made available for access on Arrowhead's 'Events and Presentations' webpage within their Investors section, ensuring stakeholders can review insights shared during the conferences.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals is dedicated to developing medicines targeting hard-to-treat diseases by silencing genes responsible for these conditions. Their robust portfolio utilizes various RNA chemistries, embracing efficient delivery systems to activate the RNA interference process effectively. Through innovative approaches, Arrowhead facilitates prompt and lasting knockdown of target genes, harnessing the RNAi mechanism inherent to living cells to inhibit specific gene expressions impacting protein production.

To stay current with developments from Arrowhead, visit their official website or follow them across various social media platforms including X (formerly Twitter), LinkedIn, Facebook, and Instagram.

Frequently Asked Questions

What is the significance of Arrowhead's upcoming conferences?

These conferences provide Arrowhead with a platform to showcase their latest research and collaborate with industry professionals.

Who will represent Arrowhead at these events?

Key personnel including Eleonora Goldberg, Christine Esau, Jennifer Hellawell, Robert Rosenson, James Hamilton, Nick Leeper, and Ira Goldberg will be presenting at various sessions.

What are the main focus areas of the presentations?

Presentations will focus on RNA-based therapies and studies related to Familial Chylomicronemia Syndrome, alongside advancements in complement-based therapies.

Where can I find the presentation materials?

Presentation materials will be accessible on Arrowhead’s 'Events and Presentations' page under the Investors section of their website.

How does Arrowhead utilize RNA interference?

Arrowhead uses RNA interference to silence problematic genes responsible for various diseases, impacting protein production and harboring the potential for therapeutic advancements.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.